{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T09:47:14Z","timestamp":1782294434442,"version":"3.54.5"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-12171-5","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T07:17:36Z","timestamp":1782285456000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Advancing engineered nanoparticles for enhanced efficacy in cancer immunotherapy: optimizing nanoparticles for cancer immunotherapy"],"prefix":"10.1007","volume":"53","author":[{"given":"Mukta","family":"Basu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Mahapatra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepika","family":"Rai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhimanyu","family":"Thakur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,24]]},"reference":[{"issue":"21","key":"12171_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12216799","volume":"12","author":"SK Daniel","year":"2023","unstructured":"Daniel SK, Sun BJ, Lee B (2023) PIPAC for gastrointestinal malignancies. J Clin Med 12(21):6799","journal-title":"J Clin Med"},{"key":"12171_CR2","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.suronc.2020.05.006","volume":"34","author":"A Di Giorgio","year":"2020","unstructured":"Di Giorgio A et al (2020) Systemic chemotherapy and pressurized intraperitoneal aerosol chemotherapy (PIPAC): A bidirectional approach for gastric cancer peritoneal metastasis. Surg Oncol 34:270\u2013275","journal-title":"Surg Oncol"},{"issue":"1","key":"12171_CR3","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.ejso.2020.05.021","volume":"47","author":"M Alyami","year":"2021","unstructured":"Alyami M et al (2021) Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for unresectable peritoneal metastasis from gastric cancer. Eur J Surg Oncol 47(1):123\u2013127","journal-title":"Eur J Surg Oncol"},{"issue":"2","key":"12171_CR4","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/jcp.27172","volume":"234","author":"FK Dermani","year":"2019","unstructured":"Dermani FK et al (2019) PD-1\/PD\u2010L1 immune checkpoint: potential target for cancer therapy. J Cell Physiol 234(2):1313\u20131325","journal-title":"J Cell Physiol"},{"issue":"2","key":"12171_CR5","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1111\/joim.12708","volume":"283","author":"P Chowdhury","year":"2018","unstructured":"Chowdhury P, Chamoto K, Honjo T (2018) Combination therapy strategies for improving PD-1 blockade efficacy: a new era in cancer immunotherapy. J Intern Med 283(2):110\u2013120","journal-title":"J Intern Med"},{"issue":"9","key":"12171_CR6","doi-asserted-by":"publisher","first-page":"3384","DOI":"10.1172\/JCI80011","volume":"125","author":"L Chen","year":"2015","unstructured":"Chen L, Han X (2015) Anti-PD-1\/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest 125(9):3384\u201391","journal-title":"J Clin Invest"},{"issue":"8","key":"12171_CR7","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1021\/acs.accounts.9b00273","volume":"52","author":"H Kobayashi","year":"2019","unstructured":"Kobayashi H, Choyke PL (2019) Near-infrared photoimmunotherapy of cancer. Acc Chem Res 52(8):2332\u20132339","journal-title":"Acc Chem Res"},{"issue":"1","key":"12171_CR8","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1515\/bmc-2022-0010","volume":"13","author":"A Mussini","year":"2022","unstructured":"Mussini A et al (2022) Targeted photoimmunotherapy for cancer. Biomol Concepts 13(1):126\u2013147","journal-title":"Biomol Concepts"},{"issue":"3","key":"12171_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24032655","volume":"24","author":"T Mohiuddin","year":"2023","unstructured":"Mohiuddin T et al (2023) Near infrared photoimmunotherapy: a review of recent progress and their target molecules for cancer therapy. International journal of molecular sciences 24(3):2655","journal-title":"International journal of molecular sciences"},{"key":"12171_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103501","author":"Y Maruoka","year":"2021","unstructured":"Maruoka Y et al (2021) Near infrared photoimmunotherapy for cancers: a translational perspective. EBioMedicine. https:\/\/doi.org\/10.1016\/j.ebiom.2021.103501","journal-title":"EBioMedicine"},{"key":"12171_CR11","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1007\/s00520-018-4046-z","volume":"26","author":"TB Brand\u00e3o","year":"2018","unstructured":"Brand\u00e3o TB et al (2018) Locally advanced oral squamous cell carcinoma patients treated with photobiomodulation for prevention of oral mucositis: retrospective outcomes and safety analyses. Supportive Care in Cancer 26:2417\u20132423","journal-title":"Supportive Care in Cancer"},{"key":"12171_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.928484","volume":"12","author":"E Austin","year":"2022","unstructured":"Austin E et al (2022) Red light phototherapy using light-emitting diodes inhibits melanoma proliferation and alters tumor microenvironments. Frontiers in Oncology 12:928484","journal-title":"Frontiers in Oncology"},{"issue":"2","key":"12171_CR13","doi-asserted-by":"publisher","first-page":"e188","DOI":"10.1016\/j.jpainsymman.2021.09.010","volume":"63","author":"P Xiao","year":"2022","unstructured":"Xiao P et al (2022) Effect of light therapy on cancer-related fatigue: a systematic review and meta-analysis. Journal of pain and symptom management 63(2):e188\u2013e202","journal-title":"Journal of pain and symptom management"},{"issue":"12","key":"12171_CR14","doi-asserted-by":"publisher","first-page":"5940","DOI":"10.1021\/acs.biomac.3c00949","volume":"24","author":"Y Ma","year":"2023","unstructured":"Ma Y et al (2023) Red-light-responsive polypeptoid nanoassemblies containing a ruthenium (II) polypyridyl complex with synergistically enhanced drug release and ROS generation for anticancer phototherapy. Biomacromolecules 24(12):5940\u20135950","journal-title":"Biomacromolecules"},{"issue":"1","key":"12171_CR15","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1093\/intimm\/dxaa037","volume":"33","author":"H Kobayashi","year":"2021","unstructured":"Kobayashi H et al (2021) Near-infrared photoimmunotherapy of cancer: a new approach that kills cancer cells and enhances anti-cancer host immunity. International Immunology 33(1):7\u201315","journal-title":"International Immunology"},{"issue":"12","key":"12171_CR16","doi-asserted-by":"publisher","first-page":"3135","DOI":"10.1515\/nanoph-2021-0119","volume":"10","author":"H Wakiyama","year":"2021","unstructured":"Wakiyama H et al (2021) Near infrared photoimmunotherapy of cancer; possible clinical applications. Nanophotonics 10(12):3135\u20133151","journal-title":"Nanophotonics"},{"issue":"22","key":"12171_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14225662","volume":"14","author":"D Nishikawa","year":"2022","unstructured":"Nishikawa D et al (2022) Near-infrared photoimmunotherapy for oropharyngeal cancer. Cancers 14(22):5662","journal-title":"Cancers"},{"issue":"10","key":"12171_CR18","doi-asserted-by":"publisher","first-page":"3941","DOI":"10.1021\/acs.molpharmaceut.0c00700","volume":"17","author":"Y-L Lum","year":"2020","unstructured":"Lum Y-L et al (2020) Cadherin-17 targeted near-infrared photoimmunotherapy for treatment of gastrointestinal cancer. Mol Pharm 17(10):3941\u20133951","journal-title":"Mol Pharm"},{"key":"12171_CR19","doi-asserted-by":"publisher","first-page":"103325","DOI":"10.1016\/j.critrevonc.2021.103325","volume":"161","author":"I Paraboschi","year":"2021","unstructured":"Paraboschi I et al (2021) Near-InfraRed PhotoImmunoTherapy (NIR-PIT) for the local control of solid cancers: Challenges and potentials for human applications. Crit Rev Oncol\/Hematol 161:103325","journal-title":"Crit Rev Oncol\/Hematol"},{"issue":"4","key":"12171_CR20","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner RC, Sterner RM (2021) CAR-T cell therapy: current limitations and potential strategies. Blood cancer J 11(4):69","journal-title":"Blood cancer J"},{"key":"12171_CR21","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s13402-021-00593-1","volume":"44","author":"M Akhoundi","year":"2021","unstructured":"Akhoundi M et al (2021) CAR T cell therapy as a promising approach in cancer immunotherapy: challenges and opportunities. Cell Oncol 44:495\u2013523","journal-title":"Cell Oncol"},{"key":"12171_CR22","doi-asserted-by":"publisher","first-page":"794183","DOI":"10.3389\/fonc.2021.794183","volume":"11","author":"Y Liu","year":"2022","unstructured":"Liu Y et al (2022) TCR-T immunotherapy: the challenges and solutions. Front Oncol 11:794183","journal-title":"Front Oncol"},{"issue":"4","key":"12171_CR23","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1158\/2326-6066.CIR-21-0307","volume":"10","author":"B Omer","year":"2022","unstructured":"Omer B et al (2022) A costimulatory CAR improves TCR-based cancer immunotherapy. Cancer Immunol Res 10(4):512\u2013524","journal-title":"Cancer Immunol Res"},{"key":"12171_CR24","doi-asserted-by":"publisher","first-page":"1113882","DOI":"10.3389\/fimmu.2023.1113882","volume":"14","author":"A Daei Sorkhabi","year":"2023","unstructured":"Daei Sorkhabi A et al (2023) The current landscape of CAR T-cell therapy for solid tumors: Mechanisms, research progress, challenges, and counterstrategies. Front Immunol 14:1113882","journal-title":"Front Immunol"},{"issue":"1","key":"12171_CR25","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41571-022-00704-3","volume":"20","author":"CL Flugel","year":"2023","unstructured":"Flugel CL et al (2023) Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours. Nat Reviews Clin Oncol 20(1):49\u201362","journal-title":"Nat Reviews Clin Oncol"},{"issue":"1","key":"12171_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-023-00373-7","volume":"12","author":"T Yan","year":"2023","unstructured":"Yan T, Zhu L, Chen J (2023) Current advances and challenges in CAR T-cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment. Experimental Hematology & Oncology 12(1):14","journal-title":"Experimental Hematology & Oncology"},{"key":"12171_CR27","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1002\/jha2.338","volume":"3","author":"S Sengsayadeth","year":"2022","unstructured":"Sengsayadeth S et al (2022) Overview of approved CAR-T therapies, ongoing clinical trials, and its impact on clinical practice. EJHaem 3:6\u201310","journal-title":"EJHaem"},{"key":"12171_CR28","doi-asserted-by":"publisher","DOI":"10.1007\/s12033-024-01090-0","author":"R Thirumalaisamy","year":"2024","unstructured":"Thirumalaisamy R et al (2024) FDA-approved chimeric antigen receptor (CAR)-T cell therapy for different cancers-a recent perspective. Molecular Biotechnology. https:\/\/doi.org\/10.1007\/s12033-024-01090-0","journal-title":"Molecular Biotechnology"},{"key":"12171_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-020-02128-1","author":"F Marofi","year":"2021","unstructured":"Marofi F et al (2021) CAR T cells in solid tumors: challenges and opportunities. Stem cell research & therapy. https:\/\/doi.org\/10.1186\/s13287-020-02128-1","journal-title":"Stem cell research & therapy"},{"key":"12171_CR30","doi-asserted-by":"publisher","first-page":"687822","DOI":"10.3389\/fimmu.2021.687822","volume":"12","author":"L Miao","year":"2021","unstructured":"Miao L et al (2021) Obstacles and coping strategies of CAR-T cell immunotherapy in solid tumors. Front Immunol 12:687822","journal-title":"Front Immunol"},{"key":"12171_CR31","doi-asserted-by":"publisher","first-page":"795164","DOI":"10.3389\/fimmu.2022.795164","volume":"13","author":"P Safarzadeh Kozani","year":"2022","unstructured":"Safarzadeh Kozani P et al (2022) Recent advances in solid tumor CAR-T cell therapy: driving tumor cells from hero to zero? Front Immunol 13:795164","journal-title":"Front Immunol"},{"key":"12171_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00128","volume":"10","author":"M Martinez","year":"2019","unstructured":"Martinez M, Moon EK (2019) CAR T cells for solid tumors: new strategies for finding, infiltrating, and surviving in the tumor microenvironment. Frontiers in immunology 10:429884","journal-title":"Frontiers in immunology"},{"key":"12171_CR33","doi-asserted-by":"crossref","unstructured":"Nguyen DT et al (2022) CAR T cell locomotion in solid tumor microenvironment. Cells, 11(12): p. 1974","DOI":"10.3390\/cells11121974"},{"key":"12171_CR34","doi-asserted-by":"crossref","unstructured":"Maia A et al (2023) CAF-immune cell crosstalk and its impact in immunotherapy. Seminars in Immunopathology. Springer","DOI":"10.1007\/s00281-022-00977-x"},{"issue":"11","key":"12171_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102353","volume":"6","author":"G Escobar","year":"2025","unstructured":"Escobar G, Berger TR, Maus MV (2025) CAR-T cells in solid tumors: challenges and breakthroughs. Cell Rep Med 6(11):102353","journal-title":"Cell Rep Med"},{"issue":"1","key":"12171_CR36","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1186\/s12943-025-02476-7","volume":"24","author":"D Shang","year":"2025","unstructured":"Shang D et al (2025) Nanoparticle-based strategy in CAR-T cell immunotherapy: challenges, implications, and perspectives. Mol Cancer 24(1):281","journal-title":"Mol Cancer"},{"issue":"1","key":"12171_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-024-01815-9","volume":"10","author":"W Wang","year":"2024","unstructured":"Wang W et al (2024) Breakthrough of solid tumor treatment: CAR-NK immunotherapy. Cell Death Discovery 10(1):40","journal-title":"Cell Death Discovery"},{"issue":"1","key":"12171_CR38","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s13046-022-02327-z","volume":"41","author":"K Pan","year":"2022","unstructured":"Pan K et al (2022) CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy. J Experimental Clin Cancer Res 41(1):119","journal-title":"J Experimental Clin Cancer Res"},{"key":"12171_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.103873","author":"S Wang","year":"2022","unstructured":"Wang S et al (2022) CAR-macrophage: an extensive immune enhancer to fight cancer. EBioMedicine. https:\/\/doi.org\/10.1016\/j.ebiom.2022.103873","journal-title":"EBioMedicine"},{"key":"12171_CR40","doi-asserted-by":"publisher","first-page":"101269","DOI":"10.1016\/j.currproblcancer.2026.101269","volume":"61","author":"S Vaja","year":"2026","unstructured":"Vaja S et al (2026) CAR-T\/NK\/M-based combination therapies in cancer: A comprehensive review. Curr Probl Cancer 61:101269","journal-title":"Curr Probl Cancer"},{"key":"12171_CR41","doi-asserted-by":"publisher","first-page":"111605","DOI":"10.1016\/j.biopha.2021.111605","volume":"139","author":"Y Chen","year":"2021","unstructured":"Chen Y et al (2021) CAR-macrophage: A new immunotherapy candidate against solid tumors. Biomed Pharmacother 139:111605","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"12171_CR42","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/s41698-025-01170-7","volume":"9","author":"M Alrehaili","year":"2025","unstructured":"Alrehaili M et al (2025) CAR-macrophages in solid tumors: promise, progress, and prospects. NPJ Precis Oncol 9(1):382","journal-title":"NPJ Precis Oncol"},{"issue":"4","key":"12171_CR43","doi-asserted-by":"publisher","first-page":"e1274","DOI":"10.1002\/cti2.1274","volume":"10","author":"M Daher","year":"2021","unstructured":"Daher M et al (2021) CAR-NK cells: the next wave of cellular therapy for cancer. Clin Translational Immunol 10(4):e1274","journal-title":"Clin Translational Immunol"},{"key":"12171_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00283","author":"RS Mehta","year":"2018","unstructured":"Mehta RS, Rezvani K (2018) Chimeric antigen receptor expressing natural killer cells for the immunotherapy of cancer. Frontiers in Immunology. https:\/\/doi.org\/10.3389\/fimmu.2018.00283","journal-title":"Frontiers in Immunology"},{"issue":"11","key":"12171_CR45","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1016\/j.ccell.2025.07.021","volume":"43","author":"A Biederstadt","year":"2025","unstructured":"Biederstadt A et al (2025) Genome-wide CRISPR screens identify critical targets to enhance CAR-NK cell antitumor potency. Cancer Cell 43(11):2069\u20132088e11","journal-title":"Cancer Cell"},{"key":"12171_CR46","doi-asserted-by":"crossref","unstructured":"Lin P et al (2025) CD70-Targeting CAR-NK Cells Overcome BCMA Downregulation and Improve Survival in High-Risk Multiple Myeloma Models. Blood Cancer Discov","DOI":"10.1158\/2643-3230.31484149"},{"issue":"11","key":"12171_CR47","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1016\/j.ccell.2025.09.013","volume":"43","author":"A Biederstadt","year":"2025","unstructured":"Biederstadt A, Rezvani K (2025) Engineered natural killer cells for cancer therapy. Cancer Cell 43(11):1987\u20132013","journal-title":"Cancer Cell"},{"key":"12171_CR48","doi-asserted-by":"publisher","first-page":"1574742","DOI":"10.3389\/fimmu.2025.1574742","volume":"16","author":"S Balkhi","year":"2025","unstructured":"Balkhi S et al (2025) CAR-NK cell therapy: promise and challenges in solid tumors. Front Immunol 16:1574742","journal-title":"Front Immunol"},{"issue":"11","key":"12171_CR49","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/j.molmed.2025.05.011","volume":"31","author":"YD Xiao","year":"2025","unstructured":"Xiao YD et al (2025) Technologies for chimeric antigen receptor transgene delivery. Trends Mol Med 31(11):1047\u20131064","journal-title":"Trends Mol Med"},{"key":"12171_CR50","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.70067","author":"HF Yin","year":"2025","unstructured":"Yin HF, Wei XJ (2025) The design of retroviral vectors used in the CAR-T products, risk management, and future perspective. Medcomm. https:\/\/doi.org\/10.1002\/mco2.70067","journal-title":"Medcomm"},{"issue":"10","key":"12171_CR51","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1097\/JOM.0000000000003166","volume":"66","author":"GR Fujimoto","year":"2024","unstructured":"Fujimoto GR et al (2024) Update on Managing the Risks of Exposure to Lentiviral and Retroviral Vectors. J Occup Environ Med 66(10):818\u2013825","journal-title":"J Occup Environ Med"},{"issue":"4","key":"12171_CR52","first-page":"813","volume":"10","author":"Q Zhang","year":"2024","unstructured":"Zhang Q et al (2024) Aptamer-Based Nongenetic Reprogramming of CARs Enables Flexible Modulation of T Cell-Mediated Tumor Immunotherapy. ACS Cent Sci 10(4):813\u2013822","journal-title":"ACS Cent Sci"},{"key":"12171_CR53","doi-asserted-by":"publisher","DOI":"10.3390\/cells14151136","author":"MA Rauf","year":"2025","unstructured":"Rauf MA et al (2025) Nanotechnology-based delivery of CRISPR\/Cas9 for cancer treatment: a comprehensive review. Cells. https:\/\/doi.org\/10.3390\/cells14151136","journal-title":"Cells"},{"issue":"9","key":"12171_CR54","doi-asserted-by":"publisher","first-page":"5397","DOI":"10.1039\/D0CS01127D","volume":"50","author":"MS de Almeida","year":"2021","unstructured":"de Almeida MS et al (2021) Understanding nanoparticle endocytosis to improve targeting strategies in nanomedicine. Chem Soc Rev 50(9):5397\u20135434","journal-title":"Chem Soc Rev"},{"issue":"8","key":"12171_CR55","doi-asserted-by":"publisher","first-page":"12567","DOI":"10.1021\/acsnano.1c02103","volume":"15","author":"S Gao","year":"2021","unstructured":"Gao S et al (2021) Nanotechnology for boosting cancer immunotherapy and remodeling tumor microenvironment: the horizons in cancer treatment. ACS Nano 15(8):12567\u201312603","journal-title":"ACS Nano"},{"key":"12171_CR56","doi-asserted-by":"publisher","first-page":"849759","DOI":"10.3389\/fimmu.2022.849759","volume":"13","author":"J Mi","year":"2022","unstructured":"Mi J, Ye Q, Min Y (2022) Advances in nanotechnology development to overcome current roadblocks in CAR-T therapy for solid tumors. Front Immunol 13:849759","journal-title":"Front Immunol"},{"issue":"3","key":"12171_CR57","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s13770-022-00515-8","volume":"20","author":"S Shin","year":"2023","unstructured":"Shin S et al (2023) Nanoparticle-based chimeric antigen receptor therapy for cancer immunotherapy. Tissue Eng Regenerative Med 20(3):371\u2013387","journal-title":"Tissue Eng Regenerative Med"},{"issue":"1","key":"12171_CR58","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1038\/s41467-025-67868-1","volume":"17","author":"T Zheng","year":"2026","unstructured":"Zheng T et al (2026) Dextran-based T-cell expansion nanoparticles for manufacturing CAR T cells with augmented efficacy. Nat Commun 17(1):1103","journal-title":"Nat Commun"},{"issue":"13","key":"12171_CR59","doi-asserted-by":"publisher","first-page":"3718","DOI":"10.1158\/0008-5472.CAN-18-0306","volume":"78","author":"F Zhang","year":"2018","unstructured":"Zhang F et al (2018) Nanoparticles that reshape the tumor milieu create a therapeutic window for effective T-cell therapy in solid malignancies. Cancer Res 78(13):3718\u20133730","journal-title":"Cancer Res"},{"issue":"3","key":"12171_CR60","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1021\/acs.nanolett.9b04246","volume":"20","author":"MM Billingsley","year":"2020","unstructured":"Billingsley MM et al (2020) Ionizable lipid nanoparticle-mediated mRNA delivery for human CAR T cell engineering. Nano Lett 20(3):1578\u20131589","journal-title":"Nano Lett"},{"issue":"11","key":"12171_CR61","doi-asserted-by":"publisher","first-page":"18408","DOI":"10.1021\/acsnano.2c06516","volume":"16","author":"H Zang","year":"2022","unstructured":"Zang H et al (2022) Ganglioside-functionalized nanoparticles for chimeric antigen receptor T-Cell activation at the immunological synapse. ACS Nano 16(11):18408\u201318420","journal-title":"ACS Nano"},{"issue":"11","key":"12171_CR62","doi-asserted-by":"publisher","first-page":"8531","DOI":"10.1021\/acsnano.4c01597","volume":"18","author":"L Zhu","year":"2024","unstructured":"Zhu L et al (2024) Engineering a Programmed Death-Ligand 1-Targeting Monobody Via Directed Evolution for SynNotch-Gated Cell Therapy. ACS Nano 18(11):8531\u20138545","journal-title":"ACS Nano"},{"issue":"17","key":"12171_CR63","doi-asserted-by":"publisher","first-page":"16770","DOI":"10.1021\/acsnano.3c03456","volume":"17","author":"T Zhu","year":"2023","unstructured":"Zhu T et al (2023) Sequential targeting hybrid nanovesicles composed of chimeric antigen receptor T-cell-derived exosomes and liposomes for enhanced cancer immunochemotherapy. ACS Nano 17(17):16770\u201316786","journal-title":"ACS Nano"},{"key":"12171_CR64","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-04171-y","author":"T Vu","year":"2026","unstructured":"Vu T et al (2026) BCMA-directed mRNA CAR T cell therapy for myasthenia gravis: a randomized, double-blind, placebo-controlled phase 2b trial. Nat Med. https:\/\/doi.org\/10.1038\/s41591-025-04171-y","journal-title":"Nat Med"},{"key":"12171_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.nantod.2024.102610","author":"JE Zhou","year":"2025","unstructured":"Zhou JE et al (2025) Lipid nanoparticles produce chimeric antigen receptor macrophages (CAR-M) in situ for the treatment of solid tumors. Nano Today. https:\/\/doi.org\/10.1016\/j.nantod.2024.102610","journal-title":"Nano Today"},{"issue":"1","key":"12171_CR66","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/s41467-025-67674-9","volume":"17","author":"K Gu","year":"2025","unstructured":"Gu K et al (2025) Intraperitoneal programming of tailored CAR macrophages via mRNA lipid nanoparticle to boost cancer immunotherapy. Nat Commun 17(1):941","journal-title":"Nat Commun"},{"issue":"23","key":"12171_CR67","doi-asserted-by":"publisher","first-page":"1900192","DOI":"10.1002\/adma.201900192","volume":"31","author":"Q Chen","year":"2019","unstructured":"Chen Q et al (2019) Photothermal therapy promotes tumor infiltration and antitumor activity of CAR T cells. Adv Mater 31(23):1900192","journal-title":"Adv Mater"},{"key":"12171_CR68","doi-asserted-by":"publisher","first-page":"1647737","DOI":"10.3389\/fmed.2025.1647737","volume":"12","author":"X Kang","year":"2025","unstructured":"Kang X, Li D, Sun R (2025) Nanotechnology and natural killer cell immunotherapy: synergistic approaches for precise immune system adjustment and targeted cancer treatment in gastrointestinal tumors. Front Med (Lausanne) 12:1647737","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"12171_CR69","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s40824-021-00246-2","volume":"25","author":"NK Lee","year":"2021","unstructured":"Lee NK, Kim S-N, Park CG (2021) Immune cell targeting nanoparticles: a review. Biomaterials Res 25(1):44","journal-title":"Biomaterials Res"},{"issue":"1","key":"12171_CR70","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13045-021-01083-5","volume":"14","author":"Y Gong","year":"2021","unstructured":"Gong Y et al (2021) Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy. J Hematol Oncol 14(1):73","journal-title":"J Hematol Oncol"},{"issue":"17","key":"12171_CR71","doi-asserted-by":"publisher","first-page":"4244","DOI":"10.1182\/bloodadvances.2020002355","volume":"4","author":"AJ Wilk","year":"2020","unstructured":"Wilk AJ et al (2020) Charge-altering releasable transporters enable phenotypic manipulation of natural killer cells for cancer immunotherapy. Blood Adv 4(17):4244\u20134255","journal-title":"Blood Adv"},{"key":"12171_CR72","doi-asserted-by":"publisher","first-page":"119418","DOI":"10.1016\/j.biomaterials.2019.119418","volume":"221","author":"K-S Kim","year":"2019","unstructured":"Kim K-S et al (2019) Multifunctional nanoparticles for genetic engineering and bioimaging of natural killer (NK) cell therapeutics. Biomaterials 221:119418","journal-title":"Biomaterials"},{"issue":"1","key":"12171_CR73","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2217\/nnm-2017-0255","volume":"13","author":"HS Sarwar","year":"2018","unstructured":"Sarwar HS et al (2018) Mannosylated thiolated polyethylenimine nanoparticles for the enhanced efficacy of antimonial drug against Leishmaniasis. Nanomedicine 13(1):25\u201341","journal-title":"Nanomedicine"},{"issue":"2","key":"12171_CR74","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1021\/acsbiomaterials.1c01532","volume":"8","author":"Z Ye","year":"2022","unstructured":"Ye Z et al (2022) In vitro engineering chimeric antigen receptor macrophages and T cells by lipid nanoparticle-mediated mRNA delivery. ACS Biomaterials Sci Eng 8(2):722\u2013733","journal-title":"ACS Biomaterials Sci Eng"},{"issue":"1","key":"12171_CR75","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1038\/s41467-024-55770-1","volume":"16","author":"S Pierini","year":"2025","unstructured":"Pierini S et al (2025) Chimeric antigen receptor macrophages (CAR-M) sensitize HER2\u2009+\u2009solid tumors to PD1 blockade in pre-clinical models. Nat Commun 16(1):706","journal-title":"Nat Commun"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12171-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-12171-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12171-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T09:03:21Z","timestamp":1782291801000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-12171-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,24]]},"references-count":75,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["12171"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-12171-5","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,24]]},"assertion":[{"value":"7 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Generative AI and AI-assisted.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"During the preparation of this work the authors used ChatGPT to correct grammar and improve sentence construction. After using this tool\/service, the authors reviewed and edited the content as needed and takes full responsibility for the content of the published article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1006"}}